Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSurrozen Inc

Surrozen Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
32.0 USD 1.00 ( 3.23%)
Last update at 2026-11-09T21:00:00Z
VOLUME
120649
Market Cap
208.86M

Momentum Score

…

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
31.09
Low
33.50
High
52 Week Price Range
11.39
Low
35.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Surrozen Inc is a clinical-stage biotech developing therapeutics that modulate the Wnt signaling pathway to promote tissue regeneration. Long-term growth drivers include clinical trial progress, partnerships using its antibody platform and unmet need for regenerative treatments. Investors may find the company attractive for its focused platform and potential for durable clinical benefits if trials succeed.

Key risks are clinical and regulatory failure, limited or no product revenue requiring additional financing, strong competition from other regenerative approaches and execution risk in advancing programs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
31.00
Dividend Yield
-
Revenue TTM
11.51M
Revenue Per Share
1.14
Gross Profit TTM
-23.07M
Debt / Equity
-0.04
ROE
-62.80%
Net Debt
-82.61M
ROCE
-272.56%
Diluted EPS TTM
-39.90

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -242.03M -63.56M -43.04M -36.00M -54.65M
Net income -242.03M -63.56M -43.04M -27.67M -52.51M
Selling general administrative 16.20M 15.06M 15.80M 19.83M 14.21M
Gross profit 2.94M 10.65M -27.23M 12.50M -
Reconciled depreciation 0.54M 1.44M 1.94M 1.96M 2.07M
Ebit -242.03M -63.56M -43.04M -46.29M -56.46M
Ebitda -241.49M -62.12M -41.13M -44.34M -54.39M
Depreciation and amortization 0.54M 1.44M 1.91M 1.96M 2.07M
Operating income -42.09M -25.54M -45.78M -44.34M -54.39M
Other operating expenses 45.57M 36.19M 45.78M 56.84M 54.39M
Interest expense - - - 1.96M 2.07M
Interest income 3.02M 1.69M 2.31M 0.78M 0.07M
Net interest income 3.02M 1.69M 2.31M 0.78M 0.07M
Income tax expense - -63.56M 2.75M -8.34M -2.14M
Total revenue 3.48M 10.65M 12.50M 12.50M 0.00M
Total operating expenses 45.03M 36.19M 18.55M 56.84M 54.39M
Cost of revenue 0.54M 1.44M 27.23M - -
Total other income expense net -199.93M -38.02M 2.74M 8.34M -0.26M
Net income from continuing ops -242.03M -63.56M -34.90M -36.00M -54.65M
Net income applicable to common shares - - - - -54.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 98.73M 48.47M 46.08M 89.44M 137.17M
Other current assets 2.11M 1.83M 2.94M 3.49M 3.34M
Total liab 286.49M 69.85M 8.14M 13.43M 27.47M
Total stockholder equity -187.76M -21.38M 37.94M 76.00M 109.70M
Other current liab 7.91M 5.18M 4.13M 6.85M 0.59M
Common stock 0.00M - - 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -527.28M -285.26M -221.69M -178.65M -142.65M
Other liab - - - - 8.30M
Other assets - - - - 0.95M
Cash 89.25M 34.56M 36.04M 24.69M 33.09M
Total current liabilities 9.93M 7.32M 7.15M 9.73M 13.57M
Current deferred revenue - - - - 8.07M
Net debt -82.61M -26.10M -32.66M -19.09M -25.30M
Short term debt 1.29M 1.83M 2.50M 2.23M 2.19M
Short long term debt total 6.64M 8.47M 3.38M 5.60M 7.79M
Other stockholder equity 339.52M 263.88M 259.63M 254.89M 252.46M
Property plant equipment - - - - 9.38M
Total current assets 91.56M 38.93M 41.13M 81.31M 105.19M
Long term investments - - - 0.00M 21.66M
Net tangible assets - - - - 109.70M
Short term investments - - 0.00M 51.15M 68.76M
Net receivables 0.21M 2.54M 2.15M 1.98M -
Inventory - - 0.00M - -
Accounts payable 0.73M 0.31M 0.53M 0.66M 2.72M
Accumulated other comprehensive income - - - -0.24M -0.12M
Non currrent assets other 0.05M 1.17M 0.40M 1.23M 0.95M
Non current assets total 7.17M 9.54M 4.95M 8.13M 31.98M
Capital lease obligations 6.64M 8.47M 3.38M 5.60M 7.79M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03M 44.14M 38.31M -77.71M
Change to liabilities - - - - 0.86M
Total cashflows from investing activities -0.13M -0.03M 51.72M - -77.71M
Total cash from financing activities 85.05M 16.18M 0.28M -2.56M 124.63M
Change to operating activities - - - - -1.08M
Net income -242.03M -63.56M -43.04M -36.00M -54.65M
Change in cash 54.68M -1.48M 11.64M -8.40M -1.89M
Begin period cash flow 35.25M 36.73M 25.09M 33.50M 35.39M
End period cash flow 89.93M 35.25M 36.73M 25.09M 33.50M
Total cash from operating activities -30.24M -17.63M -40.36M -44.15M -48.81M
Issuance of capital stock 83.78M 16.04M 0.00M 0.00M 124.22M
Depreciation 0.54M 1.44M 1.91M 1.96M 2.07M
Change to account receivables 2.33M -0.50M 0.00M -1.98M -
Sale purchase of stock 0.20M 0.09M -0.00M -2.61M -
Other cashflows from financing activities 85.05M 0.13M 0.28M 0.04M 0.41M
Change to netincome - - - - 3.99M
Capital expenditures 0.13M 0.03M 0.40M 0.73M 1.27M
Change in working capital 3.15M -0.84M -3.93M -8.42M -0.22M
Stock based compensation 3.83M 4.11M 4.37M 4.52M 2.32M
Other non cash items 204.26M 41.22M 0.33M -6.20M 1.23M
Free cash flow -30.37M -17.65M -40.76M -44.87M -50.08M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SRZN
Surrozen Inc		 1.00
3.23%		 32.00 - - 18.14 2.50 9.87 0.71
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Surrozen Inc

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

650 489 9000

https://www.surrozen.com

44

Name Title Year Born
Mr. Craig C. Parker M.B.A. CEO, Pres & Director 1962
Mr. Charles Williams Chief Financial Officer 1980
Dr. Wen-Chen Yeh M.D., Ph.D. Chief Scientific Officer 1964
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisor NA
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisor 1950
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor NA
Ms. Sheela Mohan-Peterson J.D., M.S. Sr. VP of Legal, Gen. Counsel & Corp. Sec. 1962
Dr. Geertrui Vanhove M.B.A., M.D., Ph.D. Chief Medical Officer 1966
Dr. Li Yang Ph.D. Sr. VP of Biology NA
Ms. Elizabeth Nguyen Sr. VP and Head of Talent & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…